CMS issues guidance on IMD treatment option for substance use disorders

The Centers for Medicare & Medicaid Services yesterday released guidance for state Medicaid agencies implementing Section 5052 of the SUPPORT for Patients and Communities Act of 2018, which gives states the option to cover substance use disorder treatment and withdrawal management services for adults who reside primarily in an eligible institution for mental diseases. The guidance provides information on the new state plan option, including requirements related to beneficiary and provider eligibility, clinical screenings, continuum of care, care transitions, and maintenance of existing expenditures.
Related News Articles
Headline
The Food and Drug Administration Sept. 10 released draft guidance on non-opioid treatments for treating chronic pain and reducing prescription opioid misuse.…
Headline
The Centers for Medicare & Medicaid Services Sept. 9 issued preliminary guidance regarding the implementation of certain state-directed payment provisions…
Headline
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Headline
The AHA and other national hospital organizations Sept. 5 urged Senate and House leadership to act on preventing Medicaid Disproportionate Share Hospital…
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
The Centers for Medicare & Medicaid Services today announced a nationwide initiative aimed at reinforcing eligibility standards for Medicaid and the…